International Journal of Psychiatry in Clinical Practice最新文献_第4页

The impact of the COVID-19 pandemic on mental health symptoms in new patients presenting to outpatient psychiatry. COVID-19大流行对门诊精神病学新患者心理健康症状的影响

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-02-02 DOI: 10.1080/13651501.2026.2620996

Leslie M Swanson, Sarah Bommarito, Kristina Kile, Ricks Warren, Roen Montalva, Katherine H Bullard, Vita V McCabe, Paresh D Patel, Gregory W Dalack

{"title":"The impact of the COVID-19 pandemic on mental health symptoms in new patients presenting to outpatient psychiatry.","authors":"Leslie M Swanson, Sarah Bommarito, Kristina Kile, Ricks Warren, Roen Montalva, Katherine H Bullard, Vita V McCabe, Paresh D Patel, Gregory W Dalack","doi":"10.1080/13651501.2026.2620996","DOIUrl":"10.1080/13651501.2026.2620996","url":null,"abstract":"Objective: To compare self-reported anxiety, depression, insomnia, functional impairment, and substance use among distinct cohorts of new adult psychiatric outpatients before and after the onset of the COVID-19 pandemic.Methods: Outpatient intake visit data, collected pre-pandemic (May 1, 2019-February 28, 2020) and early in the pandemic (May 1, 2020-February 26, 2021), included the Generalised Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Insomnia Severity Index (ISI), Work and Social Adjustment Scale (WSAS), and the World Health Organisation Alcohol, Smoking, and Substance Involvement Screening Test. Substance use treatment-seeking patients also completed the Brief Addiction Monitor. Analysis of variance models, adjusted for sex and race, examined between-cohort differences.Results: Among 4,197 patients (pre-pandemic: 2,434; early pandemic: 1,763), anxiety and insomnia (GAD-7, ISI) symptoms were greater after pandemic onset. Depression (PHQ-9) and functioning (WSAS) were not different. Rates of cannabis, cocaine, and inhalant use were higher post-pandemic. Among substance use treatment seekers, drug and marijuana use was higher, with women reporting more binge drinking days.Conclusions: New psychiatric outpatients who presented after the pandemic reported greater anxiety and insomnia symptoms and different substance use patterns vs. a pre-pandemic cohort, underscoring the need for targeted interventions during public health crises.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"195-202"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are critiques of ECT scaremongering or contributions to informed consent? 对电痉挛疗法的批评是危言耸听还是对知情同意的贡献？

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-02-16 DOI: 10.1080/13651501.2026.2631406

John Read, Sue Cunliffe, Sarah Price Hancock, Chris Harrop, Lucy Johnstone, Lisa Morrison

引用次数: 0

Exploration of barriers and facilitators to physical activity in adults with schizophrenia involved in a long-term psychosocial rehabilitation programme: a mixed method study. 探索长期社会心理康复项目中成人精神分裂症患者身体活动的障碍和促进因素：一项混合方法研究。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-02-04 DOI: 10.1080/13651501.2026.2622538

Alix Augustin, Mathieu Gruet, Aïna Chalabaev, Emmanuel Mulin

{"title":"Exploration of barriers and facilitators to physical activity in adults with schizophrenia involved in a long-term psychosocial rehabilitation programme: a mixed method study.","authors":"Alix Augustin, Mathieu Gruet, Aïna Chalabaev, Emmanuel Mulin","doi":"10.1080/13651501.2026.2622538","DOIUrl":"10.1080/13651501.2026.2622538","url":null,"abstract":"Objective: Regular physical activity benefits cardiometabolic health, fitness, neurocognition and quality of life in people with schizophrenia (pwSCZ). However, pwSCZ exhibit high levels of physical inactivity and poor adherence to exercise programs. This study investigated physical activity facilitators and barriers in stable pwSCZ in long-term psychosocial rehabilitation.Methods: Forty-three pwSCZ (age = 29 (12) years; n = 12 female) of a French rehabilitation centre underwent semi-structured interviews and rated pre-identified physical activity barriers and facilitators on a 5-point scale.Results: Two facilitator classifications (conventional and motivation-based) and one barrier classification emerged. Frequent facilitators included weight loss, improving well-being, enjoyment of activity and self-pride. Main barriers were fatigue, low motivation, lack of time or competing priorities, social difficulties, and addictive substance use.Conclusions: While most factors are shared with other severe mental illnesses, social difficulties, addictive substance consumption and feelings of self-pride emerged more specifically in our sample. The motivational classification highlighted the prevalence of autonomous motivation, which supports durable behaviours. Barriers reflected schizophrenia-related symptoms not addressed by antipsychotics, underlining the need for multidisciplinary care, especially as some of them are not specific to physical activity uptake. Psychosocial rehabilitation settings could use our findings to adapt physical activity promotion in pwSCZ.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"203-214"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electroconvulsive therapy in the manic phase of bipolar disorder: examining oxidative stress and effects of thiol-disulfide homeostasis. 双相情感障碍躁狂期的电痉挛治疗：检查氧化应激和硫醇-二硫化物稳态的影响。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-01-08 DOI: 10.1080/13651501.2025.2611924

Kamil Mert Angın, Sinay Önen, Salim Neşelioglu, Özcan Erel

{"title":"Electroconvulsive therapy in the manic phase of bipolar disorder: examining oxidative stress and effects of thiol-disulfide homeostasis.","authors":"Kamil Mert Angın, Sinay Önen, Salim Neşelioglu, Özcan Erel","doi":"10.1080/13651501.2025.2611924","DOIUrl":"10.1080/13651501.2025.2611924","url":null,"abstract":"Objective: Given evidence for oxidative dysregulation in bipolar disorder, we examined thiol-disulphide balance (TDB) as a redox biomarker and evaluated the impact of electroconvulsive therapy (ECT) on TDB to clarify redox contributions to BD pathophysiology.Methods: This observational mixed design study comprising cross-sectional case-control comparisons of BD-ECT(n = 31), BD-non-ECT (n = 46), healthy control (n = 42) groups and within-subject repeated-measures assessments across phases (mania, post-ECT where applicable, remission) in bipolar disorder, quantifying native thiol, disulphide, and total thiol to derive TDB ratios, with FDR-adjusted statistics.Results: Compared with healthy controls, native thiol was lower in both manic and remission phases (e.g., Mania(299.4 ± 81.16) vs. HC(379.91 ± 48.93); p < 0.001), while disulphide was higher (e.g., Remission(22.85 ± 5.07) vs. HC(17.66 ± 4.96); p < 0.001). Within the ECT group, no significant within-patient changes in TDB indices were observed across time points (all p > 0.05).Conclusion: We observed a shift of thiol-disulphide balance (TDB) towards oxidative predominance in both manic and remission phases of BD with no significant ECT-related modulation of TDB during mania. These findings highlight the need for a comprehensive examination of the impact of oxidative stress on the underlying mechanisms of BD and potential therapeutic mechanisms of ECT.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"164-171"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative effectiveness of selective serotonin reuptake inhibitors versus serotonin-norepinephrine reuptake inhibitors in the risk of diagnostic conversion from unipolar depression to bipolar disorder. 选择性5 -羟色胺再摄取抑制剂与5 -羟色胺-去甲肾上腺素再摄取抑制剂在单极抑郁症向双相情感障碍诊断转化风险中的比较效果

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2025-12-14 DOI: 10.1080/13651501.2025.2600083

Ka Hee Yoo, Kyung Joo Lee, Sang Min Lee, Changwoo Han, Rae Woong Park, Young Tak Jo

{"title":"Comparative effectiveness of selective serotonin reuptake inhibitors versus serotonin-norepinephrine reuptake inhibitors in the risk of diagnostic conversion from unipolar depression to bipolar disorder.","authors":"Ka Hee Yoo, Kyung Joo Lee, Sang Min Lee, Changwoo Han, Rae Woong Park, Young Tak Jo","doi":"10.1080/13651501.2025.2600083","DOIUrl":"10.1080/13651501.2025.2600083","url":null,"abstract":"Objective: The potential risk of diagnostic conversion from unipolar depression to bipolar disorder with antidepressant use, particularly serotonin-norepinephrine reuptake inhibitors (SNRIs) versus selective serotonin reuptake inhibitors (SSRIs), remains debated. This study aims to investigate the relationship between SSRI and SNRI use and the risk of diagnostic conversion.Methods: We conducted a retrospective cohort study using the Korean version of the Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM). The target cohort comprised patients prescribed SNRIs, while the comparator cohort included those prescribed SSRIs. The primary outcome was a new diagnosis of bipolar disorder occurring at least six months after antidepressant initiation.Results: After propensity score adjustment, no significant difference in the risk of diagnostic conversion was observed between SSRI and SNRI users. In the distributed network analysis, SNRI use was not significantly associated with an increased risk of diagnostic conversion compared to SSRI use after both 1:1 propensity score matching (hazard ratio [HR] = 1.28, 95% confidence interval [95% CI]: 0.90-1.82; I2 = 24.1%) and 1:2 propensity score matching (HR = 1.16, 95% CI: 0.88-1.53, I2 = 0%).Conclusions: This study observed no significant difference in the risk of diagnostic conversion to bipolar disorder between SSRI and SNRI users.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"155-163"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overview of systematic reviews and meta-analysis of risperidone on cardiovascular risk: analysis of Cochrane and non-Cochrane systematic reviews including 11,949 patients. 利培酮对心血管风险的系统评价和荟萃分析综述：包括11,949例患者的Cochrane和非Cochrane系统评价分析。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-03-02 DOI: 10.1080/13651501.2026.2637451

Sílvia Gianini, Igor Gianini, Andrey A Porto, Derfel R M A Folegatti, Camila M de Oliveira, David M Garner, Rodrigo D Raimundo, Vitor E Valenti

{"title":"Overview of systematic reviews and meta-analysis of risperidone on cardiovascular risk: analysis of Cochrane and non-Cochrane systematic reviews including 11,949 patients.","authors":"Sílvia Gianini, Igor Gianini, Andrey A Porto, Derfel R M A Folegatti, Camila M de Oliveira, David M Garner, Rodrigo D Raimundo, Vitor E Valenti","doi":"10.1080/13651501.2026.2637451","DOIUrl":"10.1080/13651501.2026.2637451","url":null,"abstract":"Objective: To evaluate the effects of risperidone on cardiovascular risk.Method: The searches were completed by means of EMBASE, MEDLINE/PubMed (by the National Library of Medicine), Scopus, and Web of Science databases. We included SRs of risperidone and cardiovascular risk published up to 2022. PRISMA was enforced for reporting quality, AMSTAR 2 was used to assess methodological quality, and GRADE was executed for quality of evidence analysis.Results: After excluding 1883 publications, we identified six systematic reviews, which reported effect estimates with substantial uncertainty for tachycardia events (RR 1.35, 95% CI 0.87 to 2.10), QTc prolongation events (RR 1.02, 95% CI 0.94 to 1.10), and QTc prolongation as a continuous outcome (mean difference +9.39 ms, 95% CI 4.09 to 14.69). For systolic and diastolic blood pressure, extractable mean differences (mmHg) were not reported, limiting quantitative interpretation. Overall certainty of evidence ranged from low to very low. No SR entirely adhered to the PRISMA statement, AMSTAR 2 and GRADE suggested low to very low quality.Conclusion: The available evidence from systematic reviews is of low to very low certainty and indicates substantial uncertainty regarding the cardiovascular effects of risperidone. Higher-quality systematic reviews with improved reporting and methodology are required.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"107-114"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147325947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Which clinical factors and biochemical parameters differentiate major depressive disorder with versus without lifetime psychotic symptoms? 哪些临床因素和生化参数可区分重度抑郁症伴与不伴终生精神病性症状？

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-01-09 DOI: 10.1080/13651501.2025.2611928

Cecilia Maria Esposito, Francesca Legnani, Jennifer L Barkin, Alessandro Ceresa, Guido Nosari, Martina Di Paolo, Luisa Cirella, Teresa Surace, Ilaria Tagliabue, Enrico Capuzzi, Antonios Dakanalis, Massimo Clerici, Massimiliano Buoli

{"title":"Which clinical factors and biochemical parameters differentiate major depressive disorder with versus without lifetime psychotic symptoms?","authors":"Cecilia Maria Esposito, Francesca Legnani, Jennifer L Barkin, Alessandro Ceresa, Guido Nosari, Martina Di Paolo, Luisa Cirella, Teresa Surace, Ilaria Tagliabue, Enrico Capuzzi, Antonios Dakanalis, Massimo Clerici, Massimiliano Buoli","doi":"10.1080/13651501.2025.2611928","DOIUrl":"10.1080/13651501.2025.2611928","url":null,"abstract":"Objective: Major depressive disorder (MDD) is a prevalent disabling condition, with psychotic features complicating its course and management. Purpose of the study is to identify clinical and biochemical factors differentiating psychotic from non-psychotic MDD.Methods: This is a retrospective single-centre study conducted on patients hospitalised between 2002 and 2022 at Fondazione IRCCS Policlinico (Milan, Italy) with a diagnosis of MDD. A large set of clinical and biochemical variables was collected on the first day of hospitalisation. Patients were divided according to the presence or absence of lifetime psychotic symptoms and compared by Student's t-test for continuous variables and Chi-square tests for categorical ones. The statistically significant continuous variables were inserted in a binary logistic regression model as independent predictors of lifetime psychotic symptoms.Results: No statistically significant differences in biochemical parameters (p > 0.05) were found in the two groups. The logistic regression model showed that depressed patients with lifetime psychotic symptoms had a significant longer duration of hospitalisation (p = 0.007), more lifetime suicide attempts (p = 0.035) and higher BPRS scores (p = 0.004) than the counterpart.Conclusions: Lifetime psychotic symptoms confer a more severe course of illness in patients with MDD. No biochemical parameter resulted as a biomarker of MDD psychotic subtype.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"172-179"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid treatment initiation in patients with schizophrenia: evaluation of the clinical and functional outcomes of the two-injection start regimen of aripiprazole once-monthly. 精神分裂症患者快速开始治疗：评价每月一次阿立哌唑两次注射开始方案的临床和功能结局。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2025-12-11 DOI: 10.1080/13651501.2025.2599389

Yavuz Yılmaz, Seda Yavuz, Suna Soğucak, Selim Çam

{"title":"Rapid treatment initiation in patients with schizophrenia: evaluation of the clinical and functional outcomes of the two-injection start regimen of aripiprazole once-monthly.","authors":"Yavuz Yılmaz, Seda Yavuz, Suna Soğucak, Selim Çam","doi":"10.1080/13651501.2025.2599389","DOIUrl":"10.1080/13651501.2025.2599389","url":null,"abstract":"Objective: This study aims to evaluate the short-term efficacy, safety, tolerability, and side effect profile of the two-injection start (TIS) regimen of aripiprazole once-monthly long-acting injection (AOM 400 mg) in individuals diagnosed with schizophrenia.Methods: This retrospective study included 50 patients diagnosed with schizophrenia according to DSM-5 criteria who received the TIS regimen of AOM 400 mg. Patients were divided into two groups: those followed with AOM monotherapy (Group 1) and those receiving AOM with oral agents (Group 2). Assessments included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression scales (CGI-S, CGI-I, CGI-SE), and the Global Assessment of Functioning (GAF). Evaluations were performed at baseline and at weeks 1, 2, and 4. Hospital stay duration and side effects were recorded.Results: Both groups showed significant reductions in hospital stay and PANSS scores, with improved GAF and CGI-I scores (p < 0.001). No serious side effects occurred, and mild effects resolved by week 4.Conclusion: The TIS regimen of AOM 400 mg demonstrated rapid symptomatic and functional improvement with good tolerability. Further large-scale prospective studies are warranted.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"149-154"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145742642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity. 解决艾氯胺酮临床试验的多样性差距：基于登记的性别、种族和民族的横断面分析。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-02-12 DOI: 10.1080/13651501.2026.2622532

Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc, Lukasz Szarpak, Wiesław Jerzy Cubała

{"title":"Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity.","authors":"Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc, Lukasz Szarpak, Wiesław Jerzy Cubała","doi":"10.1080/13651501.2026.2622532","DOIUrl":"10.1080/13651501.2026.2622532","url":null,"abstract":"Objective: To explore sex, racial and ethnic disparities in esketamine clinical trials for mental health disorders registered on ClinicalTrials.gov.Methods: We conducted a registry-based cross-sectional analysis of interventional esketamine trials with results posted on ClinicalTrials.gov (cut-off date: 10 February 2025). Using predefined eligibility criteria, two investigators independently extracted and verified trial-level data on sex, race, ethnicity and site locations as reported in the registry.Results: Among 13 eligible trials (n = 5116), women constituted 62.9% of participants, while men comprised 37.1%. The racial distribution included White (69.08%), Asian (13.31%), Black or African American (3.60%), and American Indian or Alaska Native (0.08%). Native Hawaiian or Other Pacific Islander participants accounted for only 0.04%. Hispanic or Latino representation ranged from 10.57% to 11.02% due to discrepancies in results reporting in trial NCT02493868.Conclusions: Esketamine clinical trials demonstrate significant racial and ethnic disparities, with underrepresentation of racial and ethnic minority groups. Regulatory efforts to improve diversity must lead to more effective recruitment for fair representation in future research.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"225-230"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement of age-related neurocognitive disorders by Ginkgo biloba extract: neuroprotection in focus. 银杏叶提取物改善与年龄相关的神经认知障碍：重点是神经保护。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-06-01 Epub Date: 2026-01-23 DOI: 10.1080/13651501.2026.2617217

Anne Eckert, Dan Georgescu, Erich Seifritz, Walter E Müller

{"title":"Improvement of age-related neurocognitive disorders by Ginkgo biloba extract: neuroprotection in focus.","authors":"Anne Eckert, Dan Georgescu, Erich Seifritz, Walter E Müller","doi":"10.1080/13651501.2026.2617217","DOIUrl":"10.1080/13651501.2026.2617217","url":null,"abstract":"Oxidative stress and enhanced free radical production with subsequent mitochondrial dysfunction and neurodegeneration are major pathomechanisms for the ageing spectrum of neurocognitive disorders ranging from subjective cognitive decline over mild cognitive impairment to Alzheimer's disease (AD) and vascular mild cognitive impairment (MCI) and vascular dementia (VD). Due to its radical scavenging, antioxidative and mitochondrial function-improving properties standardised Ginkgo biloba extracts (GBE) target several key processes of neurodegeneration. These include mitochondrial dysfunction, impaired mitochondrial quality control, and reduced energy metabolism. GBE's benefits also include supporting neuroplasticity, the brain's ability to form new neural connections, and reducing neuroinflammation, a major driver of disease progression in neurodegenerative conditions. As a consequence, GBE improves several aspects of cognitive dysfunction within the broad spectrum of neurocognitive disorders as indicated by a large body of evidence from randomised controlled studies.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"115-128"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0